Immunotherapy in breast cancer: An introduction.
The field of breast cancer immunology has progressed tremendously over the last decade. Twenty years ago immunotherapy was not considered for the treatment of breast cancers because breast cancer was not considered immunogenic. Today we know that most patients with breast cancer have some evidence of an adaptive immune response against their tumors, detectable either in the peripheral blood or in the tumor. Moreover, immunity to breast cancer begins at the earliest stages of the disease, in some patients prior to diagnosis. Recent evidence suggests that lymphocytes infiltrating breast cancers and found in the tumor stroma are strong prognostic indicators of a beneficial disease outcome. These observations now pave the way for the integration of immunomodulation into standard of care therapy for the treatment of breast cancer.
Tumor Vaccine Group, University of Washington, Seattle, WA 98195, USA. Electronic address: ndisis@uw.edu.
Mary L
ML
Disis
Tumor Vaccine Group, University of Washington, Seattle, WA 98195, USA. Electronic address: sestant2@uw.edu.
Sasha E
SE
Stanton
D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000276:immunology* / Q000628:therapy*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D016246:Lymphocytes, Tumor-Infiltrating; D059016:Tumor Microenvironment / Q000276:immunology*
D000074322:Antineoplastic Agents, Immunological
Antigen; Immune checkpoint inhibitor; Immunotherapy; Tumor infiltrating lymphocytes; Type I T-cells; Vaccine